OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (the agreement of share exchange and cooperation signed, and trading counterparts designated)
2020.Oct.06
OBI filed an application of Investigational Device Exemption (IDE) for Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424, to FDA
2020.Sep.28
OBI capital increases by issuance of stocks as the consideration of share exchange cooperation with Amaran Biotechnology Inc.
2020.Sep.28
Announcement of press release of press conference on Sept 28, 2020
2020.Sep.28
Board of directors resolved to license DNA sequence of OBI-888 to AP Bioscience Inc. for bispecific antibody development
2020.Sep.28
Board of directors’ resolution on licensing of OBI-833, OBI-888 and OBI-999 in China (including Hong Kong and Macao)
2020.Sep.28
New Appointment of Compensation Committee Member
2020.Aug.25
TFDA clearance for Phase 1 clinical study for active immunotherapeutic cancer vaccine, OBI-866
2020.Aug.25
TFDA clearance for Phase 1 clinical study for Novel Botulinum Toxin, OBI-858
2020.Aug.03
Announcement on the change of representative of corporate director
